The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

1 Apr 2009 08:10

RNS Number : 8916P
ViaLogy PLC
01 April 2009
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY") 

VIALOGY INCREASES STAKE IN SUCCESSFUL WELL

LONDONApril 1st, 2009 - ViaLogy PLC (LSE: VIY). ViaLogy announces that it has exercised an option with Atascosa Exploration LLC, of San Antonio, Texas ("Atascosa") to acquire an increased shareholding in the Galba Prospect oil well in South Central Texas ("Cindy Bartlett #2") found in March 2009 using its QuantumRD technology. ViaLogy now owns a 10% direct working interest in the Cindy Bartlett #2 well with revenue to ViaLogy expected to begin in Q2 this year. This means that ViaLogy will receive 10% of the Net Revenue Interest of the well over its lifespan. The amount of oil in the well has been calculated using industry standard core analysis practices.

 

ViaLogy has also agreed terms and dates with Atascosa for the near-term drilling of a second well on the Galba Prospect in south central Texas. Using ViaLogy's patented QuantumRD technology, the Company's scientists and Atascosa's geology and engineering team will immediately examine 3D seismic data and QuantumRD analysis to decide the optimum location position for the drilling rig. Spudding of the second well is expected to start within weeks.

ViaLogy's increased holding in Cindy Bartlett #2, and the drilling of the new well, to be called Cindy Bartlett #3, further cements the relationship with Atascosa following the success of QuantumRD which was announced on 23 March 2009 on the discovery of a series of three new oil formations at increasing depths on the Galba Prospect. The first well on the site, Cindy Bartlett #2, was drilled into the formation lying at 3,100 feet. Use of the QuantumRD seismic interpretation technology verifies the presence of hydrocarbons, permits characterization of the reservoir and porosity, and siting of the drill location. The technology is based on protected active signal processing software capable of exploiting the "noise" inherent in most seismic data. 

 

"For the immediate future we are focussing our activities on Texas," said ViaLogy's Chief Executive, Robert W. Dean. "We have a new technology that is proving its ability to improve the ratio of producing successful wells instead of dry holes, which for on-shore drilling in the continental USA currently occur in six cases out of ten. But the real secret is to combine our value-added ability to more effectively interpret the seismic data with the experience of geologists and oil men who know the areain which we work." 

"In this regard, over the past six months we've developed an excellent working relationship with Atascosa Exploration, and both companies have agreed to work closely together on future projects. So we welcomed the opportunity when Atascosa offered us a larger participation in the successful well we'd developed together."

 

Ends

 

For further information please contact:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807) Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756)

Atascosa Exploration LLC   John D. Mullins, CEO (+1 210-402-3656) 

Nominated Advisor to ViaLogy PLC (Seymour Pierce)   Mark Percy +44 (0) 20-7107-8000

Broker to ViaLogy PLC (St. Helen's Capital)

Ruari McGirr / Sebastian Wykeham +44 (0) 207 628 5582 

 

About ViaLogy: 

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUUUMUCUPBUMG
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.